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Summary
Fabry disease is a rare X-linked lysosomal storage disorder caused by the 
absence or deficiency of the hydrolase alpha-galactosidase A activity. As 
a consequence, accumulation of globotriaosylceramide occurs in a wide 
variety of cells throughout the human body. Specific gene mutations de-
termine disease severity and different phenotypes.
Fabry disease is a multisystemic disease with nonspecific initial mani-
festations. Neuropathic pain and acroparaesthesia are one of the earliest 
symptoms, already reported in childhood or adolescence. Later signs and 
symptoms involve the heart, kidney and brain, resulting in life-threatening 
complications such as cardiac and renal failure as well as cerebral strokes. 
Early treatment initiation can ameliorate disease progression and poten-
tially prevents long-term complications. 
Based on its diverse and nonspecific manifestation, it can take up to 
15 years between the onset of the first symptoms and the final diagnosis 
of Fabry disease. Recognition of early symptoms, such as neuropathic 
pain and acroparaesthesia, and considering Fabry disease in young pa-
tients with stokes, is important. 
As such, neurologists may play a key role in early diagnosis of this disease. 
Key words: Fabry disease; central nervous system; peripheral nervous system; enzyme replacement 
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Based on a lecture at the 
annual meeting 2014 of the 
Swiss Neurology Society.
Abbreviations 
ARB  = angiotensin receptors blocker  
CNS  = central nervous system 
ERT  = enzyme replacement therapy   
FOS  = Fabry Outcome Survey   
Gb3  = globotriaosylceramide  
GFR = glomerular filtration rate  
alpha-Gal A  = hydrolase alpha-galactosidase A   
MRI  = magnetic resonance imaging   
PNS  = peripheral nervous system   
SFN  = small fibre neuropathy   
TIAs  = transient ischaemic attacks  
More than 400 mutations have been identified in the 
alpha-Gal A gene (GLA gene) situated on the long arm 
of the X chromosome. For decades, Fabry disease was 
believed to be an X-linked recessive disorder. However, 
actual data suggest an X-linked dominant inheritance 
with variable penetrance. Specific gene mutations 
 determine disease phenotypes and severity [4]. Classi-
cal or typical Fabry disease is present in 1:40 000 to 
1:60 000 men and usually occurs when alpha-Gal A 
 activity is less than 1%. Milder phenotypes occur when 
gene mutations result in residual alpha-Gal A activity 
[4]. Heterozygous women, 1:6000 to 1:40 000, may also 
be affected with variable penetrance and manifesta-
tions. They can exhibit severe disease manifestation 
similar to that seen in men [4, 5]. Hwu et al. reported 
 results from a programme for newborn screening for 
Fabry disease in 171 977 infants. They found an inci-
dence of Fabry disease of approximately 1 in 1250 
males, of whom 86% carried mutations associated with 
a later- onset phenotype [6]. Underdiagnosed atypical 
phenotypes and mutations with limited alpha-Gal A 
activity might indicate that the actual incidence could 
be higher. 
Measuring alpha-Gal A enzyme activity in plasma, 
leuco cytes, cultured skin fibroblasts, biopsied tissue or 
a dried blood spot is a diagnostic tool in men. In con-
trast, women with Fabry disease may have enzyme 
 activity levels within the normal range, as a result of 
Introduction
Fabry disease, also called angiokeratoma corporis dif-
fusum, ceramide trihexosidosis, or Anderson-Fabry 
 disease, is a rare lysosomal storage disorder due to the 
absence or deficiency of hydrolase alpha-galactosidase 
A (alpha-Gal A) activity in lysosomes. This dysfunction 
results in progressive accumulation of glycosphingo-
lipids, especially of globotriaosylceramide (Gb3), 
within lysosomes in a wide variety of cells throughout 
the human body: vascular endothelial cells, neurons, 
astrocytes, meningeal cells, smooth muscle cells, as 
well as podocytes and other kidney cells, myocytes, 
etc., resulting in major organ system damage [1–3].
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random X chromosome inactivation [7]. Molecular 
 genetic testing is thus the most reliable method to 
 establish the diag nosis in females who are sympto-
matic or carriers. Prenatal testing is possible by means 
of DNA testing using chorionic villus sampling (at 9–10 
weeks) or cultured amniotic cells (amniocentesis at 
 approximately 15 weeks) [8].
Fabry disease is a multisystemic disorder, and signs 
and symptoms may appear in childhood and adoles-
cence. Among the earliest and most important organ 
 manifestations are those in the nervous system. The 
focus of this article is, therefore, to review the neuro-
logical manifestations and to enhance awareness of 
this entity. We reviewed the current literature using a 
MedLine search and congress abstracts. 
Clinical manifestation
Neurological involvement
The sphingolipid deposition can affect the entire 
 peripheral (PNS) and central (CNS) nervous systems 
 involving small and large cerebral vessels, neurons, 
ganglia, nerve sheaths and perineurium. 
Involvement of the peripheral nervous system
Small fibre neuropathy (SFN) is the main manifesta-
tion of Fabry disease in the PNS [9]. The pathophysiol-
ogy of SFN is not fully understood. Gb3 accumulation 
has been demonstrated in dermal vascular endothelial 
and perineural cells of thin myelinated Aδ and un-
myelinated C fibres involved in mediating pain and 
temperature misperception [10–13]. Electron micro-
scopy of skin biopsies revealed a decreased density of 
Aδ and C fibres [13]. With progression of the disease, 
large fibre involvement and nerve conduction abnor-
malities may develop [14]. Patients with SFN present 
with somato sensory discomfort and neuropathic pain 
as prominent manifestations. Typically, burning pain 
dysaesthesia, and paraesthesia, defined as acro-
paraesthesia, of the hands and feet occur. They may 
present as recurrent painful episodic crises triggered 
by stress, fever, heat, fatigue or exercise [15, 16]. The 
 duration may vary from a few minutes up to several 
days and extreme pain attacks known as ‘‘Fabry crises’’ 
may be accompanied by fever, joint pain and elevated 
erythrocyte sedimentation rate, and may require hos-
pitalisation [17]. During a crisis, the distal extremities 
may be livid and swollen. Neuropathic pain with 
acroparaesthesia is often the  earliest manifestation of 
Fabry disease reported by patients. Pain has been 
 reported as early as 3 years of age in boys and 6 years 
in girls [18]; mean age at onset is 14.8 years in men, 
19.8 years in women [19] (table 1). The Fabry Outcome 
Survey (FOS) reports a high frequency of neuropathic 
pain in Fabry disease (76% men, 64% women) [3, 20]. 
 Intolerance of cold and warmth is another manifesta-
tion of SNF. Quantitative sensory testing may show 
 increased or unmeasurable thermal and, specifically, 
cold detection thresholds, as well as increased vibra-
tion detection thresholds [12, 21]. Up to 63–100% of men 
and 16–33% of women have impaired sensory percep-
tion [3, 9, 22, 23].
Hypohidrosis, reduced saliva and tear production, 
 impaired pupillary constriction, heart conduction 
 defects, sexual dysfunctions such as priapism, and 
gastro intestinal disturbances may be signs and symp-
toms of peripheral autonomic dysfunction in Fabry 
disease [3, 24, 25]. 
Involvement of the central nervous system
Diffuse glycosphingolipid deposits in endothelial cells 
of small and large vessels and vascular smooth muscle 
cells may result in stenosis and occlusion as well as 
vaso dilatation and, hence, lead to impaired cerebral 
perfusion [3, 26–29]. The vertebrobasilar territory is 
preferentially affected and increased basilar artery 
 diameter has been shown to be a sensitive indicator of 
Fabry disease [30]. The higher frequency of ischaemic 
lesions in this area, furthermore, explains the typical 
CNS manifestations of vertigo, anopsia, diplopia, 
 nystagmus, dysarthria, hemiparesis, hemiataxia, and 
gait ataxia [26]. 
The mechanism linking glycosphingolipid accumula-
tion to ischaemic tissue damage is not fully under-
stood. Endothelial dysfunction, vessel wall irregulari-
ties leading to compromised cerebral blood flow 
velocities and cerebral autoregulation, and immuno-
logical and cellular changes leading to, among others, a 
prothrombotic state probably contribute to cerebral 
 ischaemia [26–29, 31, 32]. Fabry disease predisposes to 
valvular heart disease and arrhythmia, and kidney 
 disease, cardiogenic embolism and hypertension 
could also be contributory factors.
Data from FOS revealed that 13.2% (15.1% men, 11.5% 
women) of Fabry patients developed an ischaemic 
stroke or transient ischaemic attacks (TIA), and that 
 ce re brovascular events typically occur at an earlier age 
Table 1: Natural course of neurological involvement 
in Fabry disease (age in years, mean ± SD).
Men Women Ref. 
Strokes 39.8 ± 11.9 45.7 ± 14.8 [20]
Small fibre neuropathy /  
neuropathic pain
14.8 ± 1.0 19.8 ± 1.4 [19]
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in Fabry patients than in the general population [20]. 
Median age of first stroke in men was 39.8 years and 
in women 45.7 years (table 1). The observed number 
of  ischaemic strokes in men aged between 25 and 
44 years was about 12 times higher than expected in a 
comparable general population [20, 33]. Most Fabry 
 patients did not experience hypertension and athero-
sclerotic plaques before their first stroke. Approxi-
mately 50% of men and 38.5% of women experienced 
their first stroke before renal or cardiac events and 
 diagnosis of Fabry disease [3, 34–36]. In a recent 
 meta-analysis of nine studies, the prevalence of Fabry 
disease ranged from 0.6 to 11.1% among patients with 
cryptogenic strokes and from 0.4 to 3.5% in all stroke 
aetiologies [37].
Development of neuropsychiatric symptoms such as 
depression and memory deficits are frequently 
 observed in Fabry disease patients. Unlike the general 
population, men with Fabry disease report a higher 
prevalence of severe depression than women (36% 
men; 22% women) [38]. The mechanism is unclear and, 
besides a primary origin, a secondary cause due to the 
persistence of neuropathic pain has been discussed 
[38]. A large proportion of patients with Fabry disease 
also report progressive hearing impairment, tinnitus 
and dizziness and/or vertigo, presumably due to the 
involve ment of central and peripheral vestibulo- 
cochlear system [39, 40].
Neuro-imaging 
Nonspecific white and grey matter lesions, as well as 
vascular abnormalities, are often seen in brain mag-
netic resonance imaging (MRI). The most common 
structural abnormalities are found in the deep white 
matter, mostly in the posterior periventricular and 
centrum semi-ovale region [32, 41], and occur at a com-
parable frequency in male and female patients [33]. It is 
hypothesised that glycosphingolipid deposition leads 
to increased interstitial pressure in deep white matter 
and to metabolic alterations resulting in gliosis, demy-
elination and increased interstitial water content [42]. 
Calcification in the pulvinar and posterior thalamic 
 regions, on the other hand, has been shown to result 
from cerebral hyperperfusion [43, 44]. Calcification of 
the pulvinar, best seen in T1-weighted MRI (fig. 1), repre-
sents a characteristic, although not pathognomonic, 
neuroradiological feature of Fabry disease. Additional 
structures to be involved by dys trophic calcification 
are the dentate nucleus and basal ganglia [43]. Dolicho-
ectasia (fig. 2) is detectable with MRI and magnetic res-
onance angiography. A vessel diameter exceeding 
3.2 mm for the basilar artery is able to distinguish be-
tween Fabry disease patients and normal controls with 
a sensitivity of 87% and specificity of 86% p <0.001 [45]. 
With the relative risk of stroke elevated by 12.2 for men 
and 4.2 for women in the 35 to 45 year age category, 
strokes with either lacunar infarcts (fig. 3) or territorial 
infarction are usually the first serious complication 
seen in Fabry disease patients [35, 36]. 
Other organ involvement (fig. 4)
Kidney involvement is reported in about 50% of pa-
tients. Kidney lesions result from deposition of Gb3 
and other sphingolipids in the podocytes, mesangial 
Figure 1, 2: T1 magnetic resonance image (fig. 1) of a 33-year-old male with typical hyperintense pulvinar sign indicating hyperperfusion-induced 
 dystrophic calcification and magnetic resonance angiography (fig. 2) with mild elongation and dolichoectasia of the basilar artery (diameter 3.8 mm). 
Figure 3: Axial T2w magnetic resonance image of a 38-year-old female with left thalamic and subinsular infarctions.
1 2 3
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and glomerular endothelial cells, tubular cells, vessels 
and interstitial cells. It results in cellular changes, typi-
cally in prominently vacuolated podocytes and tubu-
lar cells by light microscopy (fig. 5A). Electron micros-
copy reveals lysosomal inclusions with lamellated 
structure, called myelin or zebra bodies (fig. 5B). There 
may be peritubular capillary inclusions, vascular inti-
mal and medial inclusions and vascular smooth mus-
cle cell hypertrophy in the kidneys. Vasculopathy has 
also been observed, probably due to local upregulation 
of the renin-angiotensin system [46]. Glomerular scle-
rosis and tubulointerstitial fibrosis are the histological 
features that best correlate with progression of kidney 
disease in humans with Fabry disease [47]. Kidney im-
pairment often begins with microalbuminuria and 
proteinuria in the second to third decade of life [8, 10]. 
Disease-related tubular and glomerular alterations 
lead to proteinuria and loss of glomerular filtration 
rate, resulting in chronic kidney disease. It should be 
noted that glomerular compensation (hyper filtration) 
can mask impairment of kidney function for years. For 
this reason, gradual deterioration of kidney function 
usually becomes apparent in the third to fifth decades 
of life. At this stage, fibrosis, sclerosis  and tubular 
 atrophy dominate the disease activity. By the age of 
40 years, end-stage renal disease has usually been 
reached [36, 48].
Cardiac involvement is common, affecting more than 
50% of all Fabry patients [49, 50]. It may affect all 
 cardiac structures. Intracellular accumulation of Gb3 
 occurs within myocytes, valves and vascular endo-
thelium of the heart [51]. Interstitial remodelling, 
due to intracellular lysosomal storage of Gb3 and an 
 increase of trophic factor such as lyso-Gb3, is an impor-
tant feature of Fabry cardiomyopathy [51]. In most 
Fabry  patients with cardiomyopathy, concentric left 
ventricular hyper trophy without left ventricle outflow 
tract obstruction and normal left ventricular systolic 
Figure 4: Multi-organ involvement in children (A) and adults (B) [174, 175]. * Frequent manifestations. 
GFR = glomerular filtration rate; TIA = transient ischaemic attack
B
Figure 5: Histological findings in a kidney biopsy: (A) Glomerulus with prominent, vacuolated podocytes (arrows) (H&E, ×200).  
(B) Lysosomal inclusions with lamellated structure – myeloid or zebra bodies in podocytes (TEM, ×2800).
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function is found [36, 52]. Other findings in Fabry 
cardiomyo pathy are prominent papillary muscles 
and early stages of diastolic dysfunction. Few Fabry 
 patients exhibit mild aortic, mitral and tricuspid in-
sufficiency, especially in end-stage cardiomyopathy 
[50, 52]. End-stage Fabry cardiomyopathy is charac-
terised by  intramural fibrosis, detectable by late 
gadolinium- enhanced MRI [53] and echocardiography 
[51]. This  fibrosis leads to wall motion abnormalities 
and arrhythmias [51, 54]. 
Glycosphingolipid deposition in intestinal ganglia and 
small vessels causes gastrointestinal dysmotility: epi-
sodic diarrhoea, nausea, vomiting, bloating, cramping 
abdominal pain and/or malabsorption. The median 
age of onset for these symptoms is before 15 years and, 
overall, 50% of patients with Fabry disease complain 
about gastrointestinal symptoms [55]. 
Skin involvement with angiokeratomas, clusters of 
 individual punctate (fig. 6) or scattered (fig. 7) dark red 
to blue-black angiectases, is a hallmark of Fabry dis-
ease [56]. These benign tumors, characterised by ecta-
sia of blood vessels in the papillary dermis and pos-
sibly associated with acanthosis and hyperkeratosis of 
the epidermis, are commonly localised on the lower 
trunk, palms, around the mouth and umbilicus. They 
are observed in 40–60% of patients and may appear 
 already during childhood [57]. Hypo/anhidrosis, rarely 
hyperhidrosis, occurs in Fabry disease [58]. 
Cornea verticillata is a  typical ophthalmological mani-
festation with bilateral keratopathy occuring in over 
70% patients (fig. 8). It is identifiable during slit-lamp 
examination as whirl-like white-to-golden-brown 
opacities extending from  centre to periphery of the 
cornea and corresponds to glycosphingolipid accumu-
lation in the basal epi thelium of the cornea [59]. Two 
types of lenticular changes may also be present in 
Fabry disease: anterior capsular or subcapsular cata-
ract, and radial posterior subcapsular cataract [60]. 
Posterior subcapsular cataract is rare and specific for 
Fabry disease, and hence called “Fabry cataract”. Other 
possible ocular abnormalities are retinal and conjunc-
tival vessel tortuosity [60]. 
Lung involvement with mild to severe airway obstruc-
tion, manifesting as chronic bronchitis, wheezing or 
dyspnoea, is present in 25% of women and up to 60% 
of men [61]. 
Although Fabry disease may present in childhood or 
puberty, given the rarity of this disease and the non-
specific presenting symptoms, the disease is often 
not even considered by clinicians. As a consequence, 
diagnosis of this deadly disease is delayed in a majority 
of affected patients until the underlying pathology is 
 already advanced [36, 62]. 
Management
Treatment of patients with Fabry disease primarily 
focus e s upon substitution of alpha-Gal A enzyme. 
Enzyme replacement therapy (ERT) with alpha-Gal A 
has been used to treat Fabry disease in Europe since 
2001 and in the USA since 2003. Recombinant human 
alpha-Gal A is available in two forms: agalsidase-alfa 
(Replagal®, Shire HGT) and agalsidase- beta (Fabra-
zyme®, Genzyme Corp.). Both proteins have the same 
amino acid sequence as the native human enzyme. 
They differ in glycosylation pattern. Agalsidase-alfa 
Figure 6: Angiokeratomas.
Figure 7: Angiokeratoma in the navel.
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is purified from a stable transfected line of cultured 
human skin fibroblasts and is infused at a dose of 
0.2 mg/kg every 2 weeks [63]. Agalsidase-beta is pro-
duced by expression of human alpha-Gal A DNA in 
 Chinese hamster ovary cells and is infused at a dose of 
1.0 mg/kg every 2 weeks [64]. The use of a lower mainte-
nance dose of agalsidase-beta, 0.3 mg/kg, has been 
evaluated and has been shown to maintain Gb3 clear-
ance in some, but not in all patients. Long-term clinical 
 effects of this lower dose of agalsidase-beta, however, 
have not been evaluated. Common side effects with 
ERT include infusion reactions and seroconversion 
(i.e., development of antibodies to either agalsidase- 
alfa or agalsidase-beta) [65, 66]. Studies suggest that 
there are no  significant differences between the two 
forms in terms of efficacy and safety profiles [67]. 
Neurological symptoms ameliorate with ERT. Signifi-
cant improvement of small nerve fibre function has 
been shown, resulting in decreased pain and conse-
quently less analgesic consumption [16, 65, 68, 69]. 
 Improvement in intradermal vibration and tempera-
ture perception thresholds is reported [70]. Intra-
epidermal innervation density does not increase, sug-
gesting that epidermal nerve fibres do not regenerate 
during ERT treatment. A hypothesis is that structural 
damage to small fibres is irreversible, whereas func-
tion of  remaining fibres may improve on ERT. 
CNS studies have demonstrated significant functional 
vascular changes under ERT treatment, with a ten-
dency to normalisation of cerebral vessel auto-
regulation and regional perfusion [32, 71]. However, 
 effects of ERT on white matter lesions or incidence of 
cerebrovascular events have not yet been demon-
strated [67, 68, 72]. Studies have reported recurrence of 
strokes despite long-term ERT [73, 74]. The explanation 
may be the inability of ERT to pass the blood-brain 
 barrier [75].
ERT leads to decreased left ventricular mass, heart rate 
variability and Gb3 in cardiac endothelium, as well as 
improved left ventricular function [76, 77]. It has been 
shown to stabilise kidney function and to reduce pro-
teinuria [74, 78–80].
Although there is, to date, no consensus on treatment 
initiation, studies have shown that ERT reverses 
Gb3 accumulation in cells and tissues particularly 
when started at an earlier stage of the disease, whereas 
advanced disease stages such as advanced nephro-
pathy and myocardial fibrosis do not respond to 
ERT [65, 72, 78]. Furthermore, ERT does not cure Fabry 
disease and adjunctive conventional medical treat-
ment and therapy may be required. Symptomatic 
 neuropathic pain management includes acetami-
nophen (paracetamol), gabapentin, carbamazepine 
and lamotrigine as well as tricyclic antidepressants 
such as amitriptyline.  Opioids should be used carefully 
in Fabry disease patients, in particular those with 
 gastrointestinal motility disorders; nonsteroidal in-
flammatory drugs are not recommended because of 
their nephrotoxicity. Additional measures include 
 lifestyle changes with avoidance of stimuli such as 
stress, intense physical exertion and extreme tem-
perature changes. Prophylactic therapy is particularly 
important in stroke prevention. It could include the 
use of antiplatelet agents (i.e., aspirin, clopidogrel, 
or a combination of aspirin with dipyridamole), 
 antihypertensive agents and statins. It is important 
to note, however, that the efficacy of antiplatelet and 
anticoagulant therapy has not been proven at the 
 present time. Avoidance of smoking, obesity, dyslipi-
daemia and arterial hypertension is likely to reduce 
the risk of stroke as in the general population. They 
also prevent heart failure and pulmonary symptoms. 
Angiotensin converting-enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARBs) are effective in 
reducing proteinuria and controlling hypertension 
[80]. Patients may require renal replacement therapy, 
such as dialysis or kidney transplantation. Diuretics, 
ACE inhibitors, ARBs, beta-blockers, and implantable 
cardiac devices need to be considered in patients 
with cardiovascular involvement. Heart transplanta-
tion may be necessary in cases of advanced congestive 
heart failure.
Ongoing trials are investigating novel approaches 
such as chaperone therapy [81], gene therapy [82] and 
substrate reduction therapy [83]. Further evaluations 
and pharmacological studies are needed as efficacy 
and safety in humans need to be demonstrated. 
Figure 8: Cornea verticillata.
Courtesy Dr. R. Kovacs, Ophthalmology Department, 
 University Hospital Zürich.
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Conclusions
Fabry disease is a rare multisystemic genetic disorder 
characterised by progressive accumulation of glyco-
sphingolipids in tissues, leading to ischaemia and irre-
versible vital organ damage. Neurological involvement 
by Fabry disease, presenting at the end of the first 
 decade of life or during puberty, is comparable in 
men and women and is one of the most frequent and 
earliest manifestations of Fabry disease reported by 
patients. Neurological involvement is also one of the 
earliest, potentially life-threatening, complications 
of Fabry disease with an average age of onset for cere-
brovascular ischaemia and premature stroke around 
 35–40 years. 
Because of its variable nonspecific symptoms, diagno-
sis of Fabry disease is challenging. Misdiagnoses, espe-
cially with rheumatic disorders and neurological dis-
ease, are frequent (table 2) and the delay between 
first symptoms and diagnosis could reach 10–15 years. 
Adequate care management and treatment are pro-
mising to slow or even reverse disease manifestation. 
However, organ damage is usually irreversible if treat-
ment is started too late, underscoring the importance 
of early recognition of this devastating disease.
Among patients enrolled in FOS – the Fabry Outcome 
Survey – the medical specialists who most often estab-
lish the diagnosis of Fabry disease were nephrologists 
followed by dermatologists and paediatricians; fewer 
cases are diagnosed by neurologists [3]. The earlier the 
diagnosis is suspected and confirmed and the earlier 
treatment, including ERT, is initiated, the more effec-
tive is the therapy.
Recognition of early neurological symptoms, in par-
ticular unexplained peripheral neuropathic pain 
 typically in the hands and feet, and considering Fabry 
disease in the case of unexplained stroke in young 
 patients is important. 
To avoid misdiagnosis and to start treatment early, 
young patients with unexplained stroke should be 
evaluated for presence of other systemic problems in 
their personal medical and family history such as (i) 
gastrointestinal disturbance, (ii) recurrent tingling or 
burning in hands or feet, (iii) pain crises of pain possi-
bly accompanied by fever remaining of unexplained 
origin, (iv) trouble sweating, (v) difficulties to tolerate 
heat or cold, and (vi) a family history of kidney/cardiac 
failure, ischaemic attack or stroke and early death. A 
complete physical examination should be performed 
to look for angiokeratomas, reddish-purple spots 
 particularly in the bathing trunk area. Neurological 
examination should focus on sensations mediated 
by  pe ripheral small fibres, such as cold, heat, light 
touch, pressure and vibration perception testing. Pro-
teinuria has to be sought (table 3). 
In conclusion, Fabry disease requires a multidiscipli-
nary approach, including  neurologists, nephrologists, 
cardiologists, dermatologists, gastroenterologists, ge-
neticists, pathologists and clinical pharmacologists. 
Neurologists play a key role in the early diagnosis of 
this deadly disease and may be the first clinicians to 
identify Fabry disease.
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Table 2: Common misdiagnoses of Fabry disease (not an exhaustive list).
Fabry disease symptoms May be diagnosed as
Diarrhoea and abdominal  
pain
Gluten/lactose intolerance, noninflammatory 
bowel diseases
[84]
Acute pain in extremities Erythromelalgia, “growing pains” [85, 86]
Angiokeratomas Lupus, petechiae, Osler disease [3, 87]
Elevated erythrocyte 
 sedimentation rate
Juvenile or rheumatoid arthritis, rheumatic 
disorders, fibromyalgia, rheumatic fever
[87]
Joint pain Juvenile or rheumatoid arthritis, rheumatic 
disorders
[87]
Stroke-like events in 
 brainstem structures
Multiple sclerosis [88–90]
Table 3: Signs and symptoms suggestive of Fabry disease.
Personal medical history
Gastrointestinal disturbance
Acroparaesthesia, burning pain in hands or feet
Neuropathic pain of unknown cause
Trouble sweating
Vertigo, dizziness
Heat/cold intolerance
Transient ischaemic attacks
Stroke
Family history
Kidney disease
Cardiac disease
Transient ischaemic attacks 
Stroke
Early death
Physical examination
Angiokeratomas
Cold, heat and vibration perception testing
Laboratory examination
Proteinuria
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